Monitoring of plasma imatinib concentration for the effective treatment of CML patients [2]

Leukemia Research

Volumn 28, Issue 10, 2004, Pages 1117-1118

  Tsutsumi, Yutaka ^a   Kanamori, Hiroe ^a   Yamato, Hiroaki ^a   Ehira, Nobuyuki ^a   Miura, Takuya ^a   Kawamura, Takahito ^a   Obara, Shinji ^a   Tanaka, Junji ^b   Asaka, Masahiro ^b   Imamura, Masahiro ^b   Masauzi, Nobuo ^a  

^a Hakodate Municipal Hospital   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; MESSENGER RNA; PROTEIN TYROSINE KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; BODY WEIGHT; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; DRUG BLOOD LEVEL; DRUG EFFICACY; ETHNIC DIFFERENCE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LETTER; LOW DRUG DOSE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BODY HEIGHT; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL STROMAL TUMORS; HUMANS; JAPAN; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 3843062407     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.03.002     Document Type: Letter

References (3)

1. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:2001;1031-1037
2. Bakhitar R., Lohne J., Ramos L., Khemani L., Hayes M., Tse F. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec™) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. 768:2002;325-340
3. Horikoshi A., Takei K., Sawada S. Effect of lower dose of imatinib to CML patients. Leuk. Res. 27:2003;1167